文献速递药物不良反应与药物警戒特殊人群用药

荷兰新冠疫苗接种后月经异常:自发报告与纵向患者报告数据描述

Menstrual abnormalities after COVID-19 vaccination in the Netherlands: A description of spontaneous and longitudinal patient-reported data.
PubMed 文献 · Br J Clin Pharmacol · 2023-06-25

CEM研究显示≤54岁女性发生率为41.4/1000,25-34岁年龄组(OR 2.18;95%CI 1.45-3.41)和辉瑞疫苗(OR 3.04;95%CI 2.36-3.93)与月经异常显著相关,提示新冠疫苗接种与月经异常的关系是合理的,需进一步研究。

要点

  • ≤54岁女性接种新冠疫苗后月经异常发生率41.4/1000,自发报告数据支持该观察。
  • 闭经/月经过少与月经过多合计约占所有报告异常的一半。
  • 25-34岁年龄组(OR 2.18;95%CI 1.45-3.41)和辉瑞疫苗(OR 3.04;95%CI 2.36-3.93)与月经异常显著相关。

核心结论

  • 队列研究显示≤54岁女性月经异常发生率较高,自发报告分析支持该观察,提示新冠疫苗接种与月经异常的关系是合理的,需进一步研究。

研究设计与样本

  • 总结荷兰药物警戒中心Lareb自发报告系统2021年2月至2022年4月收到的月经异常报告。
  • 对前瞻性队列事件监测(CEM)研究中报告的月经异常进行logistic回归分析,评估个人特征、既往SARS-CoV-2感染及激素避孕药使用与接种后月经异常的关联。

主要发现

  • CEM研究显示≤54岁女性月经异常发生率为41.4/1000。
  • 闭经/月经过少与月经过多合计约占所有报告异常的一半。
  • 25-34岁年龄组OR 2.18(95%CI 1.45-3.41),辉瑞疫苗OR 3.04(95%CI 2.36-3.93)。
  • BMI及所评估的大多数合并症与月经异常无显著关联。

临床怎么用

  • 临床药学智能体医生在接种咨询中可告知≤54岁女性接种后月经异常发生率约41.4/1000,多数表现为闭经/月经过少或月经过多。
  • 对25-34岁女性及接种辉瑞疫苗者,可关注月经异常报告,但需结合个体情况评估,不据此改变接种建议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: During the COVID-19 vaccination campaigns, the number of reports of menstrual abnormalities increased rapidly. Here, we describe the nature and potential risk factors associated with menstrual abnormalities based on spontaneously reporting data as well as data from a prospective cohort event monitoring (CEM) study as these are poorly studied. METHODS: Reports of menstrual abnormalities received by the Netherlands Pharmacovigilance Centre Lareb in the spontaneous reporting system between February 2021 and April 2022 were summarized. In addition, logistic regression analysis was performed on the reported menstrual abnormalities in the CEM study to assess the association between person characteristics, prior SARS-CoV-2 infection and use of hormonal contraceptives and the occurrence of menstrual abnormalities after vaccination. RESULTS: We analysed over 24 000 spontaneous reports of menstrual abnormalities and over 500 episodes (among 16 929 included women) of menstrual abnormalities in the CEM study. The CEM study showed an incidence of 41.4 per 1000 women aged ≤54 years. Amenorrhoea/oligomenorrhoea and heavy menstrual bleeding collectively accounted for about half of all abnormalities reported. Significant associations were observed for the age group 25-34 years (odds ratio 2.18; 95% confidence interval 1.45-3.41) and the Pfizer vaccine (odds ratio 3.04; 95% confidence interval 2.36-3.93). No association was observed for body mass index and presence of most comorbidities assessed. CONCLUSION: The cohort study showed a high incidence of menstrual disorders among women aged ≤54 years, and this observation was supported by the analysis of spontaneous reports. This suggests that a relation between COVID-19 vaccination and menstrual abnormalities is plausible and should be further investigated.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Duijster JW, Schoep ME, Nieboer TE, et al. Menstrual abnormalities after COVID-19 vaccination in the Netherlands: A description of spontaneous and longitudinal patient-reported data. Br J Clin Pharmacol. 2023. PMID: 37222170. doi:10.1111/bcp.15799

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。